Table 1.
Signs/symptoms | ICBD dataset (p1) | German cohort (p2) | Turkish cohort (p3) | Innsbruck cohort | ||
---|---|---|---|---|---|---|
Total | Austrian origin (p4) | Turkish origin | ||||
Oral aphthae | 98%* | 99% | 100% | 93% | 94% | 94% |
Genital aphthae | 74%* | 65%# | 80%* | 62% | 56% | 53% |
Skin manifestations | 70%** | 73%# | 93%** | 47% | 56%# | 24% |
Ocular manifestations | 55%# | 43%† | 35% | 46% | 56% | 47% |
Musculoskeletal manifestations | 51%* | 52% | 74% | 65% | 67% | 59% |
Neurological manifestations | 17% | 20% | 4%* | 21% | 22% | 24% |
Vascular manifestations | 19%* | 21% | 12%* | 30% | 22% | 29% |
Urological manifestations | 7% | 15%† | 0%n.d. | 7% | 6% | 12% |
Gastrointestinal manifestations | 6%** | 17%† | 0%** | 21% | 11%# | 41% |
Cardiological manifestations | 2% | 3% | 0%n.d. | 3% | 0% | 6% |
Lung manifestations | 2%** | 6%† , # | 0%n.d. | 11% | 11% | 18% |
Renal manifestations | 0%n.d. | 2%† | 0%n.d. | 1% | 0% | 6% |
Positive pathergy test | 47% | 31% | n.d. | 40% | 33% | 67% |
Family history positive for ABD | 11%* | 4%† | n.d. | 26% | 14% | 38% |
HLA‐B51 positivity | 51% | 43%† | n.d. | 56% | 47%# | 11% |
Data are given for the Innsbruck cohort (with subgroups of defined Austrian and Turkish background, n = 18 and n = 17, respectively) compared to international patients recruited for the International Criteria for Behçet's Disease (ICBD) dataset,14 from the German cohort (n = 7125) and a Turkish cohort (n = 10713). P‐values are calculated using Fisher's exact test of significance (#P < 0.1; *P < 0.05; **P < 0.01) for comparison between the ICBD dataset with data of the total Innsbruck cohort (p1), between the Austrian patients of the Innsbruck cohort and those of the German cohort (p2), and between the Turkish patients of the Innsbruck cohort and those of the Turkish cohort (p3). †Data from patients with German origin (representing 39% of the German cohort, including those with significant differences to the total German cohort). ABD, Adamantiades–Behçet's disease; HLA, human leukocyte antigen; n.d., not described.